Journal article
Cancer risk and survival in path-MMR carriers by gene and gender up to 75 years of age: A report from the Prospective Lynch Syndrome Database
P Møller, TT Seppälä, I Bernstein, E Holinski-Feder, P Sala, DG Evans, A Lindblom, F Macrae, I Blanco, RH Sijmons, J Jeffries, HFA Vasen, J Burn, S Nakken, E Hovig, EA Rødland, K Tharmaratnam, WH De Vos Tot Nederveen Cappel, J Hill, JT Wijnen Show all
Gut | BMJ PUBLISHING GROUP | Published : 2018
Abstract
Background: Most patients with path-MMR gene variants (Lynch syndrome (LS)) now survive both their first and subsequent cancers, resulting in a growing number of older patients with LS for whom limited information exists with respect to cancer risk and survival. Objective and design: This observational, international, multicentre study aimed to determine prospectively observed incidences of cancers and survival in path-MMR carriers up to 75 years of age. Results: 3119 patients were followed for a total of 24 475 years. Cumulative incidences at 75 years (risks) for colorectal cancer were 46%, 43% and 15% in path-MLH1, path-MSH2 and path-MSH6 carriers; for endometrial cancer 43%, 57% and 46%; ..
View full abstractGrants
Awarded by Suomen Lääketieteen Säätiö
Funding Acknowledgements
This work was supported by The Finnish Cancer Foundation; The Sigrid Juselius Foundation; The Finnish Medical Foundation; Jane and Aatos Erkko Foundation; Finnish State Research Funding; the Swedish Cancer Society; the Swedish Research Council; the Stockholm Cancer Society; the Norwegian Radium Hospital Foundation; the Wales Gene Park funded by Health and Care Research Wales; and the Spanish Ministry of Economy and Competitiveness and co-funded by FEDER funds- a way to build Europe- (SAF2012-33636 and SAF2015-68016); the Carlos III Health Institute; RTICC (RD12/0036/0031); the Scientific Foundation Asociacion Espanola Contra el Cancer; and the Government of Catalonia (2014 SGR 338). D Gareth Evans is an NIHR senior investigator. Mark Jenkins has a fellowship from the National Health and Medical Research Council of Australia.